22 studies found for:    HCV | Open Studies | Interventional Studies | United States, Florida | Adult | Phase 2, 3, 4
Show Display Options
Rank Status Study
1 Recruiting Safety and Efficacy of SOF/VEL/GS-9857 FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis
Condition: Hepatitis C Virus Infection
Interventions: Drug: SOF/VEL/GS-9857;   Drug: SOF/VEL
Age Groups: Adult / Senior
2 Recruiting Safety and Efficacy of SOF/VEL/GS-9857 FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor
Condition: Hepatitis C Virus Infection
Interventions: Drug: SOF/VEL/GS-9857;   Drug: SOF/VEL
Age Groups: Adult / Senior
3 Recruiting Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy
Condition: Hepatitis C
Interventions: Drug: SOF/VEL/GS-9857;   Drug: Placebo
Age Groups: Adult / Senior
4 Recruiting Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy
Condition: Hepatitis C
Interventions: Drug: SOF/VEL/GS-9857;   Drug: SOF/VEL
Age Groups: Adult / Senior
5 Recruiting Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
Conditions: Chronic Hepatitis C;   Hepatitis C Virus;   Compensated Cirrhosis;   Severe Renal Impairment;   End-stage Renal Disease
Interventions: Drug: ombitasvir/paritaprevir/ritonavir;   Drug: dasabuvir;   Drug: Ribavirin
Age Groups: Adult / Senior
6 Recruiting Efficacy and Safety of MK-3682B (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)
Conditions: Hepatitis;   Hepatitis C;   Digestive System Diseases;   Flaviviridae Infections;   Hepatitis, Viral, Human;   Liver Diseases;   RNA Virus Infections;   Virus Diseases
Interventions: Drug: MK- 3682B;   Drug: Ribavirin
Age Groups: Adult / Senior
7 Recruiting Efficacy and Safety of Grazoprevir (MK-5172) and MK-3682 With Elbasvir (MK-8742) or MK-8408 for Chronic Hepatitis C Genotype (GT) 1 and GT2 Infection (MK-3682-011)
Condition: Hepatitis C
Interventions: Drug: Grazoprevir;   Drug: MK-3682;   Drug: Elbasvir;   Drug: MK-8408;   Drug: MK-3682B;   Drug: Ribavirin
Age Groups: Adult / Senior
8 Recruiting A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection
Conditions: Chronic Hepatitis C;   Hepatitis C Virus
Interventions: Drug: ABT-493;   Drug: ABT-530;   Drug: Ribavirin (RBV);   Drug: ABT-493/ABT-530
Age Groups: Adult / Senior
9 Recruiting Efficacy and Safety of Grazoprevir (MK-5172) and MK-3682 With Elbasvir (MK-8742) or MK-8408 for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3 Infection (MK-3682-012)
Condition: Hepatitis C
Interventions: Drug: Grazoprevir;   Drug: MK-3682;   Drug: Elbasvir;   Drug: MK-8408;   Drug: MK-3682B;   Drug: RBV
Age Groups: Adult / Senior
10 Recruiting A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis
Conditions: Hepatitis C Virus Infection;   Chronic Hepatitis C;   Compensated Cirrhosis
Intervention: Drug: ABT-493/ABT-530
Age Groups: Adult / Senior
11 Recruiting A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection
Conditions: Chronic Hepatitis C;   Hepatitis C Virus;   HCV
Intervention: Drug: ABT-493/ABT-530
Age Groups: Adult / Senior
12 Recruiting Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency
Condition: HCV Infection
Interventions: Drug: SOF 100 mg;   Drug: SOF 400 mg;   Drug: RBV;   Drug: LDV/SOF
Age Groups: Adult / Senior
13 Recruiting Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
Condition: HIV Infections
Interventions: Drug: ABT-450/r/ABT-267;   Drug: ABT-333;   Drug: Ribavirin
Age Groups: Adult / Senior
14 Recruiting A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
Conditions: Chronic Hepatitis C;   Hepatitis C Virus;   Genotype 3 Hepatitis C Virus
Interventions: Drug: ABT-493/ABT-530;   Drug: sofosbuvir;   Drug: daclatasvir
Age Groups: Adult / Senior
15 Recruiting A Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Sofosbuvir and RBV in DAA Treatment-experienced Adults With Chronic Hepatitis C Virus Infection
Condition: Chronic Hepatitis C Infection
Interventions: Drug: Ombitasvir/ABT-450/r;   Drug: Dasabuvir;   Drug: Sofosbuvir;   Drug: Ribavirin
Age Groups: Adult / Senior
16 Recruiting Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection
Condition: Hepatitis C Virus
Interventions: Drug: Simeprevir 150 mg;   Drug: Daclatasvir 60 mg;   Drug: Sofosbuvir 400 mg
Age Groups: Adult / Senior
17 Recruiting Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies
Condition: Hepatitis C Virus Infection
Interventions: Drug: LDV/SOF;   Drug: RBV
Age Groups: Adult / Senior
18 Recruiting A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection
Condition: Chronic Hepatitis C Virus (HCV) Infection
Intervention: Drug: ABT-493/ABT-530
Age Groups: Adult / Senior
19 Recruiting A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection
Condition: Chronic Hepatitis C Virus (HCV) Infection
Interventions: Drug: ABT-493/ABT-530;   Drug: Placebo for ABT-493/ABT-530
Age Groups: Adult / Senior
20 Recruiting A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma
Condition: Chronic Hepatitis C Infection
Interventions: Drug: Ombitasvir/Paritaprevir/Ritonavir;   Drug: Dasabuvir;   Drug: Ribavirin
Age Groups: Adult / Senior

   Previous Page Studies Shown (1-20) Next Page (21-22) Show next page of results    Last Page
Indicates status has not been verified in more than two years